<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680794</url>
  </required_header>
  <id_info>
    <org_study_id>PA18053</org_study_id>
    <nct_id>NCT03680794</nct_id>
  </id_info>
  <brief_title>Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies</brief_title>
  <official_title>sCD160 in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CD160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal
      antibody directed against human CD160 reduced angiogenesis of endothelial cells with a
      distinct mechanism from current angiogenic therapies that target the VEGF/VEGF-R pathway. A
      soluble form of CD160, sCD160, has been found to be highly expressed in the vitreous and the
      sera of patients with severe diabetic retinopathies, and can now be dosed with help of an
      ELISA test.

      The investigators aim to evaluate the association between ischaemic retinopathies (patients
      with or without) and sCD160 concentrations in the vitreous, the aqueous humour and the serum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      120 patients enrolled for ophthalmic surgery (cataract or posterior segment surgery
      (epiretinal membrane, macular hole, vitrectomy)) will be recruited in the Department of
      Ophthalmology, Robert Debr√© Hospital, Reims, France.

      Each patient will benefit a complete ophthalmologic examination, and either an aqueous
      sampling (cataract) or a vitreous sampling (posterior segment) along with a serum sampling at
      the beginning of the surgery. ELISA test will be performed on vitreous or aqueous samples in
      triplicates. Luminex will be performed on vitreous samples in order to determine the
      concentrations of several ischemia biomarkers (VEGF, PlGF, Platelet-derived growth factor
      (PDGF-B), SDF-1, Angpt2, InterIeukin IL-6, IL-8, CD105, Monocyte chemoattractant protein 1
      (MCP-1), IL-10, interferon-inducible protein-10 ( IP-10), IL-1B and CD106, RAGE).

      Primary objective is:

      - Evaluation of the association between ischaemic retinopathies (patients with or without)
      and sCD160 concentrations of the vitreous or the aqueous humours.

      Secondary objectives are:

        -  Evaluation of the association between diabetic retinopathies (patients with or without)
           and sCD160 concentrations of the vitreous, the aqueous humours and the sera.

        -  Evaluation of the association between several vitreous biomarkers of ischaemia and
           sCD160 concentrations of the vitreous and the sera.

        -  Evaluation of the association between sCD160 concentrations in the vitreous and the
           sera.

        -  Evaluation of the association between sCD160 concentration in the aqueous humours and
           the sera.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sCD160 concentration in the vitreous humor</measure>
    <time_frame>Day 0</time_frame>
    <description>ELISA test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sCD160 concentration in the aqueous humor</measure>
    <time_frame>Day 0</time_frame>
    <description>ELISA test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sCD160 concentration in the serum</measure>
    <time_frame>Day 0</time_frame>
    <description>ELISA test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic retinopathy severity</measure>
    <time_frame>Day 0</time_frame>
    <description>Angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular endothelial growth factor (VEGF)</measure>
    <time_frame>Day 0</time_frame>
    <description>LUMINEX test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placenta Growth Factor-1(PlGF)</measure>
    <time_frame>Day 0</time_frame>
    <description>LUMINEX test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stromal cell-derived factor 1 (SDF-1)</measure>
    <time_frame>Day 0</time_frame>
    <description>LUMINEX test</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Patients with ophthalmic surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sampling of ophthalmic liquid</intervention_name>
    <description>aqueous sampling for patients with cataract surgery or vitreous sampling for patients with posterior segment surgery</description>
    <arm_group_label>Patients with ophthalmic surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        inclusion criteria :

          -  over 18 years old

          -  with social security affiliation

          -  willing to participate this study non-inclusion criteria :

          -  any prior (3 months) or concomitant treatment with anti-VEGF therapy, corticosteroids,
             or immunosuppressive agents

          -  any history of previous vitreoretinal surgery, ocular tumor, severe ocular trauma,
             severe intraocular, periocular infection, inflammation, or radiation

          -  any serious allergy to the fluorescein sodium for injection in angiography

          -  any history of previous systemic anti-VEGF treatment

          -  any history of inflammatory or auto-immune disease

          -  any active extraocular inflammation or infection in the last 4 weeks before surgery
             exclusion criteria :

          -  Patients with C-reactive protein CRP &gt; 10mg/mL (serum sampling during surgery)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carl ARNDT</last_name>
    <phone>326787090</phone>
    <phone_ext>0033</phone_ext>
    <email>carndt@chu-reims.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien JOLLY</last_name>
      <phone>326788472</phone>
      <phone_ext>33</phone_ext>
      <email>djolly@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

